TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET 19
1.4 CURRENCY AND PRICING 21
1.5 LIMITATION 21
1.6 MARKETS COVERED 21
2 MARKET SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHIC SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 CURRENCY AND PRICING 26
2.5 RESEARCH METHODOLOGY 27
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
2.7 DBMR MARKET CHALLENGE MATRIX 31
2.8 MARKET APPLICATION COVERAGE GRID 32
2.9 DBMR VENDOR SHARE ANALYSIS 33
2.10 SECONDARY SOURCES 34
2.11 ASSUMPTIONS 34
3 MARKET OVERVIEW 35
3.1 DRIVERS 37
3.1.1 RISING NUMBER OF CHRONIC DISEASES 37
3.1.2 RISING AGING POPULATION 38
3.1.3 GROWING NUMBER OF DIAGNOSTIC CENTERS 39
3.1.4 INCREASE IN THE RESEARCH AND DEVELOPMENTAL ACTIVITIES OF CONTRAST AGENTS 40
3.2 RESTRAINT 42
3.2.1 SIDE EFFECTS ASSOCIATED WITH CONTRAST AGENTS 42
3.3 OPPORTUNITIES 42
3.3.1 RISING HEALTHCARE EXPENDITURE 42
3.3.2 INCREASE IN NUMBER OF PUBLIC AND PRIVATE HOSPITALS 45
3.4 CHALLENGE 46
3.4.1 LACK OF AWARENESS REGARDING THE PROPER DOSAGE OF CONTRAST AGENT 46
4 EXECUTIVE SUMMARY 47
5 PREMIUM INSIGHTS 50
6 KEY PRIMARY INSIGHTS 53
7 GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY AGENT TYPE 54
7.1 OVERVIEW 55
7.2 IODINATED CONTRAST MEDIA 56
7.3 BARIUM-BASED CONTRAST MEDIA 57
7.4 MICROBUBBLE CONTRAST MEDIA 57
7.5 GOLD NANOPARTICLE CONTRAST AGENTS 58
7.6 OTHERS 58
8 GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY APPLICATION 59
8.1 OVERVIEW 60
8.2 CARDIOLOGY 62
8.2.1 PERCUTANEOUS CORONARY INTERVENTION 63
8.2.2 STRUCTURAL HEART DISEASE 63
8.2.3 CONGENITAL HEART DISEASE 63
8.2.4 ELECTROPHYSIOLOGY 63
8.3 GASTROENTEROLOGY 63
8.4 NEUROLOGY 64
8.5 ONCOLOGY 64
8.6 UROLOGY 65
8.7 GENERAL SURGERY 65
9 GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY END USER 66
9.1 OVERVIEW 67
9.2 IMAGING CENTERS 68
9.3 HOSPITAL 69
9.4 CLINICS 69
9.5 DIAGNOSTIC CENTER 70
9.6 AMBULATORY SURGICAL CENTERS 70
9.7 PRIVATE PRACTICES 71
10 GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, BY GEOGRAPHY 72
10.1 OVERVIEW 73
10.2 NORTH AMERICA 78
10.2.1 U.S. 84
10.2.2 CANADA 86
10.2.3 MEXICO 88
10.3 EUROPE 90
10.3.1 GERMANY 96
10.3.2 U.K. 98
10.3.3 FRANCE 100
10.3.4 ITALY 102
10.3.5 SPAIN 104
10.3.6 SWITZERLAND 106
10.3.7 NETHERLANDS 108
10.3.8 RUSSIA 110
10.3.9 BELGIUM 112
10.3.10 TURKEY 114
10.3.11 REST OF EUROPE 116
10.4 ASIA PACIFIC 117
10.4.1 CHINA 123
10.4.2 JAPAN 125
10.4.3 INDIA 127
10.4.4 AUSTRALIA 129
10.4.5 SOUTH KOREA 131
10.4.6 SINGAPORE 133
10.4.7 MALAYSIA 135
10.4.8 INDONESIA 137
10.4.9 THAILAND 139
10.4.10 PHILIPPINES 141
10.4.11 REST OF ASIA PACIFIC 143
10.5 SOUTH AMERICA 144
10.5.1 BRAZIL 150
10.5.2 REST OF SOUTH AMERICA 152
10.6 MIDDLE EAST & AFRICA 153
10.6.1 SOUTH AFRICA 159
10.6.2 REST OF MIDDLE EAST & AFRICA 161
11 GLOBAL CONTRAST AND IMAGING AGENTS IN INTERVENTIONAL X-RAY MARKET, COMPANY LANDSCAPE 162
11.1 COMPANY SHARE ANALYSIS; GLOBAL 162
11.2 COMPANY SHARE ANALYSIS; NORTH AMERICA 163
11.3 COMPANY SHARE ANALYSIS; EUROPE 164
11.4 COMPANY SHARE ANALYSIS; ASIA PACIFIC 165
12 COMPANY PROFILES 166
12.1 BRACCO 166
12.1.1 COMPANY SNAPSHOT 166
12.1.2 GEOGRAPHICAL PRESENCE 166
12.1.3 COMPANY SHARE ANALYSIS 167
12.1.4 PRODUCT PORTFOLIO 167
12.1.5 RECENT DEVELOPMENTS 168
12.2 GENERAL ELECTRIC COMPANY 169
12.2.1 COMPANY SNAPSHOT 169
12.2.2 REVENEUE ANALYSIS 169
12.2.3 COMPANY SHARE ANALYSIS 170
12.2.4 PRODUCT PORTFOLIO 170
12.2.5 RECENT DEVELOPMENTS 170
12.3 GUERBET 171
12.3.1 COMPANY SNAPSHOT 171
12.3.2 REVENEUE ANALYSIS 171
12.3.3 COMPANY SHARE ANALYSIS 172
12.3.4 PRODUCT PORTFOLIO 172
12.3.5 RECENT DEVELOPMENTS 173
12.4 FUJIFILM VISUALSONICS INC. 173
12.4.1 COMPANY SNAPSHOT 173
12.4.2 GEOGRAPHICAL PRESENCE 174
12.4.3 PRODUCT PORTFOLIO 175
12.4.4 RECENT DEVELOPMENT 175
12.5 IMAX 176
12.5.1 COMPANY SNAPSHOT 176
12.5.2 GEOGRAPHICAL PRESENCE 176
12.5.3 PRODUCT PORTFOLIO 177
12.5.4 RECENT DEVELOPMENT 177
?
12.6 J.B. CHEMICALS & PHARMACEUTICALS LTD. 178
12.6.1 COMPANY SNAPSHOT 178
12.6.2 REVENUE ANALYSIS 178
12.6.3 PRODUCT PORTFOLIO 179
12.6.4 RECENT DEVELOPMENT 179
12.7 JODAS EXPOIM 180
12.7.1 COMPANY SNAPSHOT 180
12.7.2 GEOGRAPHICAL PRESENCE 180
12.7.3 PRODUCT PORTFOLIO 181
12.7.4 RECENT DEVELOPMENTS 181
12.8 LANTHEUS MEDICAL IMAGING, INC. 182
12.8.1 COMPANY SNAPSHOT 182
12.8.2 REVENUE ANALYSIS 182
12.8.3 PRODUCT PORTFOLIO 183
12.8.4 RECENT DEVELOPMENTS 183
12.9 NANO THERAPEUTICS PVT. LTD. 184
12.9.1 COMPANY SNAPSHOT 184
12.9.2 GEOGRAPHICAL PRESENCE 184
12.9.3 PRODUCT PORTFOLIO 185
12.9.4 RECENT DEVELOPMENT 185
12.10 NOVALEK PHARMACEUTICALS PVT. LTD. 186
12.10.1 COMPANY SNAPSHOT 186
12.10.2 GEOGRAPHICAL PRESENCE 186
12.10.3 PRODUCT PORTFOLIO 187
12.10.4 RECENT DEVELOPMENT 187
12.11 TAEJOON PHARM 188
12.11.1 COMPANY SNAPSHOT 188
12.11.2 GEOGRAPHICAL PRESENCE 188
12.11.3 PRODUCT PORTFOLIO 189
12.11.4 RECENT DEVELOPMENT 189
12.12 UNIJULES LIFE SCIENCES LTD. 190
12.12.1 COMPANY SNAPSHOT 190
12.12.2 PRODUCT PORTFOLIO 190
12.12.3 RECENT DEVELOPMENT 190
13 QUESTIONNAIRE 191
14 RELATED REPORTS 194
?